Silent Nucleotide Polymorphisms and a Phylogeny for Mycobacterium tuberculosis by Baker, Lucy et al.
Much remains unknown of the phylogeny and evolu-
tion of Mycobacterium tuberculosis, an organism that kills 2
million people annually. Using a population-based
approach that analyzes multiple loci around the chromo-
some, we demonstrate that neutral genetic variation in
genes associated with antimicrobial drug resistance has
sufficient variation to construct a robust phylogenetic tree
for M. tuberculosis. The data describe a clonal population
with a minimum of four distinct M. tuberculosis lineages,
closely related to M. bovis. The lineages are strongly geo-
graphically associated. Nucleotide substitutions proven to
cause drug resistance are distributed throughout the tree,
whereas nonsynonymous base substitutions unrelated to
drug resistance have a restricted distribution. The phyloge-
netic structure is concordant with all the previously
described genotypic and phenotypic groupings of M. tuber-
culosis strains and provides a unifying framework for both
epidemiologic and evolutionary analysis of M. tuberculosis
populations. 
M
ycobacterium tuberculosis has caused tuberculosis
(TB) in humans for thousands of years (1,2), and the
World Health Organization (WHO) estimates that one
third of the global population is infected with M. tubercu-
losis (3); however, the bacterium has remained an enigma.
The global resurgence of TB highlights the need for an
improved understanding of its epidemiology and its evolu-
tionary biologic features. Recent advances in molecular
characterization of M. tuberculosis isolates, which index
variation in insertion sequences (4) and repetitive genom-
ic elements (5,6), have elucidated clusters of identical and
closely related strain families (7–9). These findings have
provided insights into regional (10) and national (11) epi-
demiologic features. However, these techniques may be
less suited to global population and evolutionary analyses,
and integrating information obtained from different
approaches is complex (12). Genomic comparisons have
identified genetic variation for population screening; how-
ever, these analyses are limited to those sites that vary
between the compared genomes and are potentially mis-
leading (13–15). Nucleotide sequences provide robust,
portable, and comparable data for studying population
variation. The mutational processes that generate this vari-
ation are understood, and sequence data have been suc-
cessfully used in the study of bacterial epidemiology,
population biology, and evolution (16). The complete
genome sequences (15–18) provide access to all regions of
the chromosome and facilitate such studies. However,
high-throughput gene sequencing of structural genes (19)
and host immune system protein targets (20) in M. tuber-
culosis isolates indicated low levels of sequence diversity.
Although extensive genomic sequencing was performed in
both studies, comparable sequence data were obtained on
a limited number of highly selected isolates. 
We used an unbiased population approach to analyze
genetically silent nucleotide sequence variation for seven
unlinked loci distributed around the chromosome. The loci
chosen were genes associated with antimicrobial drug
resistance that have been reported to possess >95% of all
sequence variation observed in 26 structural genes studied
(19), which includes >90% of synonymous nucleotide sub-
stitutions, i.e., nucleotide substitutions that do not affect
the translated amino acid. In a population sample of 316
U.K. clinical isolates, silent single nucleotide polymor-
phisms (sSNPs) resolve an unambiguous phylogeny and
provide a unifying framework for epidemiologic, popula-
tion, and evolutionary analyses.
Methods
Bacterial Strains
The 316 M. tuberculosis clinical isolates were identi-
fied in England and Wales from January 1, 1998, through
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isolates (n = 216) resistant to one or both of the firstline
antituberculous drugs (rifampicin and isoniazid) and 100
randomly chosen fully susceptible isolates. One M. tuber-
culosis H37Rv isolate, four M. bovis isolates, two M.
africanum type I isolates, and one M. microti isolate were
included for comparison. M. tuberculosis complex isolates
were identified with a combination of microscopic and
macroscopic appearance, growth characteristics, biochem-
ical analysis, and DNA hybridization (21). Clinical and
epidemiologic information were obtained from laboratory
records at the HPA Mycobacterium Reference Unit,
London, UK, the U.K. Mycobacterial Resistance Network
database (MYCOBNET), and the 1998 national TB survey
(22).Duplicate isolates were excluded. Drug susceptibility
was determined by the resistance ratio method (2). Strains
were characterized by IS6110 restriction fragment length
polymorphism (RFLP) and spoligotyping (4,5)
Amplifying and Sequencing Target Gene Loci
The nucleotide sequences were obtained for the follow-
ing seven gene loci: rpoB, katG, oxyR, ahpC, pncA, rpsL,
and gyrA. These gene loci are associated with drug resist-
ance, but without antimicrobial drug selection pressure,
they would be regarded as housekeeping genes. Primers
and amplification conditions for polymerase chain reaction
(PCR) are shown in Table 1. Products were purified by
precipitation with 20% polyethylene glycol–2.5 mol/L
NaCl and sequenced from both DNA strands by using
internal nested primers (Table 2) and BigDye Ready
Reaction Mix (ABI, Warrington, UK) according to the
manufacturer’s instructions. Unincorporated dye termina-
tors were removed by precipitation with 96%
ethanol–0.115 mol/L sodium acetate, pH 4.6. The reaction
products were separated and detected with an ABI prism
3700. 
Genetic Analysis
Sequences were assembled with the STADEN suite of
computer programs (23). The sequences were compared,
and isolates with identical sequences were assigned the
same allele number. For each gene, the DNAsequence was
translated in frame, and each nucleotide polymorphism
characterizing the allele was classified as synonymous or
genetically silent, nonsynonymous, or intergenic. 
For each isolate, the concatenated sequences from the
coding region of all seven gene loci were reduced to a 36-
nt sequence motif, constituting a synonymous sequence
profile (SSP), and distinct SSPs were assigned a synony-
mous sequence type (SST). Phylogenetic analysis of the
SST motifs was performed with the MEGA (24) and
PHYLIP software packages (25): 225 isolates were
sequenced at all loci. The sequencing data from the initial
225 isolates demonstrated key polymorphisms that were
lineage defining. The remaining 94 isolates were assigned
a lineage based on polymorphisms at katG87, katG609,
katG1388, oxyR37, oxyR285, and ahpC–46, and by the spoligo-
type deletion pattern. A lineage was only ascribed if all
data points agreed (Table 3). The relationship between lin-
eages, phenotypic and genotypic drug resistance, and
country of birth was analyzed with chi-square and Fisher
exact test.
Comparison with Outgroups
An in silico analysis of the seven gene loci was under-
taken for two mycobacterial outgroups, M. leprae (26) and
M. marinum with BLAST (Sanger Institute, Cambridge,
UK; available from http//www.sanger.ac.uk/projects/
M_marinum/). The complete gene sequences for each of
the seven loci in M. tuberculosis, M. bovis, M. leprae, and
M. marinum were aligned in frame by using Clustal-W.
Two approaches were used. First, the aligned sequences
for the coding regions of the seven gene loci were con-
catenated to produce a single sequence of 8.212 Kbp for
each isolate. The concatenated sequences for fully suscep-
tible examples of the M. tuberculosis SSTs were aligned to
this. Second, SSPs were constructed for M. leprae and M.
marinum by using the relevant aligned nucleotide for each
of the previously identified variable synonymous sites in
M. tuberculosis and M. bovis. For each approach, a phy-
logeny was constructed with the neighbor-joining tree
method, and the results were compared.
TbD1-PCR Analysis
Three isolates per SST were selected for analysis. Each
possessed, when possible, a different IS6110 RFLP or
spoligotype pattern. This analysis was performed with the
published method (13).
Results
Observed Genetic Diversity
The complete gene was sequenced for all but one locus,
which provided 8,318 Kbp of nucleotide sequence data for
each isolate. Across the seven loci, 115 variable sites were
identified, of which 101 were within the coding region of
the selected loci, and 36 were associated with genetically
neutral base substitutions. The number of alleles per locus
varied from 6 (oxyR) to 40 (rpoB). The proportion of vari-
able sites present at each locus was low, 0.68% (rpoB) to
2.68% (pncA). Nonsynonymous base substitutions were
more frequent than synonymous substitutions at almost all
loci. The ratio of nonsynonymous substitutions per non-
synonymous site to synonymous substitutions per synony-
mous site (dN /dS ratio) varied from 0.109 to 0.848 in
sensitive M. tuberculosis isolates and from 0.301 to 1.952
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medication is indeed the selective force at most loci. Five
variable sites were unique to M. bovis, of which four were
associated with synonymous polymorphisms. A further
variable site with a previously reported synonymous poly-
morphism (katG C609T) (27) was identified in both M. bovis
and  M. microti, present in all four M. bovis isolates
sequenced and the published M. bovis genome sequence
(18). 
Synonymous Sequence Types and Lineages
By disregarding nonsynonymous polymorphisms, i.e.,
those producing an amino acid change likely in response to
diversifying or stabilizing selection, a subset of 37 neutral
sSNPs at 36 sites was generated; one site possessed two
different synonymous substitutions. These substitutions
occurred in 35 unique combinations, which we term syn-
onymous sequence types (SSTs); each was assigned an
arbitrary number (Figure 2). The variation in the SSTs
conformed to the clonal model for bacterial population
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Table 1. Amplification primers 
Gene/locus Forward  primer  Reverse  primer 
Product 
(bp) 
Reaction 
conditions
a Cycles
gyrA  gyrA-ext F 
5c-ACAGACACGACGTTGCCGCC-3c 
gyrA-ext R 
5cc-GTCGATTTCCCTCAGCATCTCC-3c
435  95°C for 15 min
 b
95°C for 15 s 
68°C for 30 s 
72°C for 1 min 
72°C for 5 min 
30 
inhA  mabA-ext F 
5c-TCGTAGGGCGTCAATACACC-3c 
mabA-ext R 
5c-TCATTCGACCGAATTTGTTG-3c 
605  94°C for 5 min 
94°C for 30 s 
60°C for 30 s 
72°C for 30 s 
72°C for 5 min 
30 
katG-ext3F 
5c-CGACGAAATGGGACAACAGT-3c 
katG-ext3R 
5c-TGCATGAGCATTATCCCGTA-3c 
1,507  94°C for 5 min 
94°C for 30 s 
60°C for 30 s 
72°C for 1 min 
72°C for 7 min 
30 
katG 
katG -ext5F 
5c-TCGACTGTGCTGTTGGCGAGG-3c
katG-ext5R 
5c-CTTCGCCGACGAGGTCGTGG-3c 
1,531  95°C for 15 min
 b
95°C for 30 s 
68°C for 30 s 
72°C for 1 min 
72°C for 7 min 
30 
oxyR-ahpC  oxyR-ext F 
5c-TCGAGCTGCGACGGTGCTGG-3c 
oxyR-extR 
5c-CTGCGGGTGATTGAGCTCAGG-3c
1,437  95°C for 15 min
 b
95°C for 30 s 
72°C for 30 s 
72°C for 1 min 
72°C for 7 min 
30 
pncA  pncA-ext F 
5cc-AACCAAGGACTTCCACATCG-3c 
pncA-extAR 
5c-CAGAAACTGCAGCATCATCG-3c 
1,324  95°C for 15 min
 b
95°C for 30 s 
64°C for 30 s 
72°C for 1 min 
72°C for 7 min 
30 
rpoB-46F 
5c-GGCCGTGGGCACCGCTCC-3c 
rpoB 1868R 
5c-CCAGCGGGGCCTCGCTACG-3c 
1,822  95°C for 15 min
 b
95°C for 15 s 
65°C for 30 s 
72°C for 3 min 
72°C for 10 min 
30 
rpoB 
rpoB 1711F 
5c-GTGCCCTCGTCTGAGGTGGAC-3c
rpoB 3602R 
5c-AAGACCGATGCGGAGTTCATCG-3c
1,891  95°C for 15 min
 b
95°C for 15 s 
65°C for 30 s 
72°C for 3 min 
72°C for 10 min 
30 
rpsL rpsL-extF 
5c-GGCCGACAAACAGAACGT-3c 
rpsL-extR 
5c-GTTCACCAACTGGGTGAC-3c 
494  94°C for 5 min 
94°C for 30 s 
56°C for 30 s 
72°C for 30 s 
72°C for 5 min 
30 
aA final PCR reaction volume of 25 PL was used that contained 2.5 PL of 10 x ammonium sulfate reaction buffer (Bioline, London, UK), 1.5 mmol/L 
magnesium chloride (Bioline); 200 Pmol/L each of dATP, dTTP, dGTP, and dCTP;, 300 nmol/L of each primer pair, 0.8 units of Taq DNA polymerase 
(Bioline), 1 PL (|10 ng) of template DNA and sterile distilled water. Amplification was carried out in 0.2 ml thin-wall polymerase chain reaction tubes in a 
DNA Thermal Cycler 9600 (Applied Biosystems, Warrington, UK). Products were purified by precipitation with 20% polyethylene detected with an ABI 
Prism 3700 or an ABI Prism 377 automated DNA sequencer (ABI, Warrington, UK).  
bReaction performed with Hotstar Taq and reaction buffer (Qiagen, Crawley, UK).
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}structure (28), and the maximum parsimony method gen-
erated a phylogenetic tree with no homoplasies, i.e., the
lack of independent occurrence of a polymorphism in more
than one branch of the tree (Figure 1A, 2). Each branch
corresponds to a unique combination of sSNPs. The phy-
logeny was robust, whether constructed with or without
outgroup SSTs generated from the M. leprae and M. mar-
inum genome sequences. The analysis identified four
prominent M. tuberculosis lineages (numbered I to IV); the
M. bovis isolates formed an additional lineage. The lineag-
es are defined by distinct combinations of sSNPs (Figure
2). Virtually all of the nodes in the tree are occupied; inter-
nal nodes tend to be represented more frequently in the iso-
late population. Although a number of evolutionary
scenarios are possible, the most likely explanation for this
observation is that the sSNP variation arose recently.
Within the M. tuberculosis complex, the sSNPs clearly
distinguish M. tuberculosis from M. bovis and M. microti,
with the M. microti SST forming a node on the M. bovis
lineage. The M. africanum type 1 isolates sequenced could
not be distinguished from M. tuberculosis because they
share SST-1. 
SST Phylogeny and Population Subdivisions
A variety of approaches have been used previously to
subdivide  M. tuberculosis strains into definable groups.
These include assignments based on two nonsynonymous
polymorphisms in katG and  gyrA (19); the presence or
absence of a TB-specific genomic region of difference,
TbD1 (13); variation within the genomic direct repeat
region demonstrated by spoligotyping; and strain families
defined by highly conserved DNA fingerprint patterns
obtained by RFLP of the insertion element IS6110. Each
technique defines a limited number of distinct subdivisions,
which although different, overlap when techniques are
compared. The sSNP phylogenetic tree was congruent with
all of the previously described subdivisions (Figure 1). 
katG and gyrA Polymorphisms
M. tuberculosis isolates can be divided into three
groups (1–3) based on two apparently unselected nonsyn-
onymous SNPs, katG G 1388 T, and gyrAG 284 C (19). Group 1
is defined by the combination of katG 1388 T and gyrA 284 C,
group 2 by katG 1388 G and gyrA 284 C, and group 3 by katG
1388 G and gyrA 284 G. We characterized the katG-gyrA poly-
morphisms in all isolates. The katG G 1388 T polymorphism
cosegregated in all cases with the synonymous base sub-
stitution rpoB T 3243 C found in lineages I, III, IV, and M.
bovis, whereas the gyrA G 284 C polymorphism subdivided
SST-2 in lineage II. Group 1 isolates can therefore be sub-
divided into three prominent M. tuberculosis lineages (I,
III, and IV) made up of 21 SSTs and M. bovis. Group 2 and
3 M. tuberculosis isolates are subdivisions of lineage II.
Group 2 isolates can be further subdivided into 10 SSTs,
whereas group 3 isolates are confined to a subdivision of
SST 2 (Figure 1B). When the SST of the clinical isolate
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Table 2. Sequencing primers
a 
Locus/PCR product  Forward primers  Reverse primers 
gyrA  gyrA-1F 5c-CAGCTACATCGACTATG-3c gyrA-1R  5c-GGGCTTCGGTGTACCTCAT-3c 
inhA promoter  mabA-1F 5c-AGAAAGGGATCCGTCATGGT-3c mabA-1R  5c-GTCACATTCGACGCCAAAC-3c 
katG-1F 5c-ACGCGGGGTCTGACAAAT-3c katG-1R  5c-GACAAGGCGAACCTGCTTAC-3c 
katg-2F 5c-GTAAGCAGGTTCGCCTTGT-3c katG-2R  5c-TCGGGATTGACTGTCTCACA-3c 
katG 3F-3R 
katG-3F 5c-ATCTCTTCCAGGGTGCGAAT-3c katG-3R  5c-GAGTGGGAGCTGACGAAGAG-3c 
katG-4F 5c-AGAGGTCAGTGGCCAGCAT-3c katG-4R  5c-AGATGGGGCTGATCTACGTG-3c 
katG-5F 5c-GCTGTTTCGACGTCGTTCAT-3c katG-5R  5c-ACTACGGGCCGCTGTTTATC-3c 
katG 5F-5R 
katG-6R 5c-ACACTTCGCGATCACATCC-3c katG-6R  5c-ACACTTCGCGATCACATCC-3c 
oxyR–1 5c-CTGGCCAGGTAAGACGACC-3c oxyR-2  5c-CAGACGCTCGATGCTGCC-3c 
oxyR-7 5c-TCATATCGAGAATGCTTGCGG-3c oxyR-4  5c-TGCTTGGCGTCCACCTTGG-3c 
oxyR-ahpC 
oxyR-6 5c-TGATGTCTTTGGCGTACTCGG–3c oxyR-6  5c-CAATGACGAGTTCGAGGACC-3c 
pncA-P1 5c-GCTGGTCATGTTCGCGATCG-3c pncA-R  5c-CGATGAAGGTGTCGTAGAAGC-3c  pncA 
pncA –F 5c-AACCAAGGACTTCCACATCG–3c pncA-2F  5c-ATACCGACCACATCGACCTC-3c 
rpoB –41F 5c-GTGGGCACCGCTCCTCTAAGG-3c  rpoB 509R 5c-TGACCACCACACGCTCGGTCC-3c 
rpoB 331F 5c-CGTTTCGACGATGTCAAGGCA-3c  rpoB 975R 5c-GTCGACGACGTGATGGGCTCG-3c 
rpoB 783F 5c-CTGGAGAAGGACAACACCGTCG-3c  rpoB 2 5c-GCACGTCGCGGACCTCCAGCC-3c 
rpoB–46-1868 
rpoB 1 5c-GGTCGGCATGTCGCGGATGGA-3c rpoB  1845R  5c-CGCTACGGACCAGCGGCACC-3c 
rpoB 1725F 5c-GGTGGACTACATGGACGTCTC-3c rpoB  2313R  5c-GTCGGAGATGTTCGGGATGTCG-3c 
rpoB 2134F 5c-GAGATGGCGCTGGGCAAGAAC-3c rpoB  2770R  5c-TCTGGCCGATGTTCATCCGTCG-3c 
rpoB 2600F 5c-AGCTGGTGCGTGTGTATGTGG-3c rpoB  3213R  5c-GGCCTGCATGCCCCAGCACTCC-3c 
rpoB 1711-3602 
rpoB 3013F 5c-CCGTTCCCGTACCCGGTCACG-3c rpoB  3581R  5c-GAAGAAGTTGACGTCGAGCAC-3c 
rpsL  rpsL F 5c-ACGTGAAAGCGCCCAAGATAGA -3c rpsL  R  5c-ACCAACTGCGATCCGTAGACC-3c 
aAll sequencing reactions were performed in 96-well plates (Abgene, UK) in a DNA Thermal Cycler 9600 (Applied Biosystems, Warrington, UK) by using 
the following thermocycling conditions: 30 cycles of denaturation at 96°C for 10 s, annealing at 50°C for 5 s, and extension at 60°C for 2 min. 
 CDC1551 was identified in silico by analysis of the rele-
vant sequences (www.tigr.org), it shared the same
sequence type, SST 2, as the other isolate for which a com-
plete genome is available, H37Rv. Although these two iso-
lates are distinguished by numerous other synonymous and
nonsynonymous polymorphisms (15), these organisms are
closely related, which has implications for genetic varia-
tion based on comparing the two complete genome
sequences (14,29).
TbD1 Region of Difference
The presence or absence of DNA regions, identified by
genomic comparisons of M. tuberculosis H37Rv and M.
bovis BCG, can be used to distinguish the closely related
members of the M. tuberculosis complex. However, only
two groups of M. tuberculosis isolates have been described
with this approach, defined by the presence or absence of
the TB-specific region, TbD1 (13). TbD1 PCR analysis
was performed on three epidemiologically unrelated iso-
lates from each SST, when available. We found that the
TbD1 region was present in all 13 SST types constituting
lineage IV and all M. bovis, M. microti, and M. africanum
type I isolates, but the region was absent from all other lin-
eages and SSTs (Figure 1C). This finding implies that the
TbD1 deletion occurred before both the katG G 1388 T and
the rpoB T 3243 C mutations. Although SST-1 appears the
least differentiated SST with the maximum parsimony
method and sSNPdata alone, when taken together with the
TbD1 data, the ancestors of lineage IV are likely to have
diverged from M. africanum type I, M. microti, and M.
bovis before differentiation of the other M. tuberculosis
lineages.
DNA Fingerprinting Techniques
Molecular epidemiologic analyses of TB populations
use a combination of typing techniques, most commonly
IS6110 RFLP analysis and spoligotyping. Spoligotyping
has been used to distinguish members of the M. tuberculo-
sis complex (5,30), and together with IS6110 RFLP, has
been used to describe various M. tuberculosis strain fami-
lies including Beijing (7), Haarlem (8), Africa (8), Delhi
(9), East Africa-India (EA-I), and Latin America-
Mediterranean (12). Both techniques were used to type all
316 isolates, producing 234 IS6110 RFLPpatterns and 263
spoligotyping patterns; 157 isolates were assigned to strain
families. 
All isolates within each family were confined to a sin-
gle lineage (Figure 1D). Furthermore, each lineage was
defined by a distinct pattern of spacer deletions
(Figure 1E). The signature spoligotype spacer deletion pat-
tern for lineage II (lack of probe hybridization at spacers
33–36) concurs with that previously noted in group 2 and
group 3 M. tuberculosis isolates (13,31). Lineage I was
defined by the signature spoligotype of the Beijing family
(absence of spacers 1–34), and lineage IV by the signature
spoligotype of the EA-I family. The remaining strain
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Figure 1. Unifying phylogeny for Mycobacterium tuberculosis. A)
Maximum parsimony tree of M. tuberculosis and M. bovis based
on 37 silent single-nucleotide polymorphisms in 225 isolates.
Synonymous sequence types (SST) are marked 1–35. The fre-
quency of each SST is marked in parentheses. The nodes of the
major lineages are highlighted: lineage I (cyan), lineage II (red),
lineage III (blue), lineage IV (yellow), and M. bovis (green). The
colors correspond to those in Figure 2. Note both M. africanum
Type I isolates sequenced were SST 1. B) Schematic representa-
tion of the genetic groups 1, 2, and 3 defined by the katG-gyrA
scheme. C) Schematic representation of the presence or absence
of the tuberculosis specific region of difference, TbD1. D)
Schematic representation of the strain families Beijing, Haarlem,
Africa, Delhi, East Africa-India (EA-I), and Latin America-
Mediterranean (LA-M), previously described by IS6110 restriction
fragment length polymorphism typing and spoligotyping, demon-
strating concordance with the phylogenetic tree. E) Spoligotyping
patterns for representative isolates of each lineage demonstrating
lack of probe hybridization at spacers 1–34 in lineage I, 33–36 in
lineage II, 4–7 and 23–24 in lineage III, 29–32 and 34 in lineage
IV, and 39–43 in M. bovis. families were confined to lineage subbranches, including
the Haarlem family, confined to SSTs 4, 5, and 6 of line-
age II, and the Delhi family, confined to lineage III, almost
exclusively within SSTs 11, 12, 13, 26, and 27. The rela-
tionship between SST, lineage, spoligotype pattern, and
IS6110 RFLP pattern are shown in more detail in online
Figure available at http://www.cdc.gov/ncidod/eid/vol10
no9/04-0046-G2.htm.
Seventy-one isolates shared identical RFLP and spolig-
otype patterns with one or more isolate, grouped in 23
clusters, of which 10 possessed RFLP patterns containing
five or fewer IS6110 copies. Cluster sizes ranged from two
to seven isolates, with a median cluster size of two. Isolate
clusters were present in all lineages, but isolates with low
copy number were confined to lineage II and IV. Three of
the low copy number clusters, each characterized by a sin-
gle IS6110 band and distinct spoligotype pattern, were
subdivided by SST, whereas among high copy number
clusters, all isolates within a cluster possessed the same
SST. To prevent introducing a selection bias, no correction
was made for strain transmission.
Polymorphisms and Antimicrobial 
Drug Resistance to Lineage
Having demonstrated a robust phylogeny for M. tuber-
culosis on the basis of neutral genetic variation, we anno-
tated the tree with the nsSNPs. Most nsSNPs were rare
within the isolate collection examined, many of which
were represented uniquely. However, a number of nsSNPs
known to confer drug resistance occurred frequently,
including rpoB C 1367 G, rpoB C 1367 T, rpoB C 1351 T (32,33),
katG A 944 C (34,35), rpsL A 128 G (36), and inhA C–15 T pro-
moter mutation (35). These polymorphisms were distrib-
uted throughout the phylogeny, which implies that they
arose independently on many occasions, presumably in
response to the positive selection imposed by antimicro-
bial drug use. In contrast, an intergenic SNP, oxyR-ahpC G
-46 A (37), associated with, but not proven to cause, isoni-
azid resistance, occurred exclusively in lineage III and was
present in all isolates within the lineage, which implies that
this SNP may have arisen under neutral selection.
Although mutations conferring drug resistance were
present in all lineages, the proportion of resistant and sus-
ceptible isolates varied between lineages. When antimicro-
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Figure 2. Abbreviated figure demonstrating the relationship between the silent single nucleotide polymorphisms, the synonymous
sequence type, and the major lineages (abbreviated to 26 SSTs and 26 variable sites. •, represents invariant base with respect to SST
1. For full reproduction of this figure, please see http://www.cdc.gov/ncidod/eid/vol10no9/04-0046-G2.htm).bial drug susceptibility data were used, lineage III was
positively associated with isoniazid resistance (51/62, p =
0.002), Lineages I and III were positively associated with
streptomycin resistance (12/20, p = 0.0004 and 24/62, p =
0.004 respectively), and lineage IV was positively associ-
ated with fully susceptible isolates (30/62, p = 0.002).
Rifampicin resistance was not associated with any lineage.
Genotypic analysis of phenotypically resistant isolates
showed that among isoniazid-resistant isolates, the resist-
ance-conferring mutation katG A 944 C was positively asso-
ciated with lineage III (odds ratio [OR] 2.44, p = 0.016)
and the inhA C –15 T promoter mutation positively associat-
ed with lineage IV (OR 3.28, p = 0.006). Among strepto-
mycin-resistant isolates, the resistance-conferring
mutation rpsL A 128 G was positively associated with lineage
I (OR 7.83, p = 0.012) and negatively associated with lin-
eage II (OR 0.32, p = 0.036). No genotype-lineage associ-
ation was identified for rifampicin resistance. Different
lineages have significant differences in their antimicrobial
drug susceptibility to certain antimicrobial agents, perhaps
demonstrating the effect of genomic environment on the
probability of mutational events conferring resistance to
these antimicrobial drugs. 
Lineage to Country of Birth
Drug resistance in countries with low TB incidence has
been associated with foreign-born migrants (11); 44% of
TB cases in England and Wales occur in the indigenous
population (22). Information about country of birth was
available for 225 (71%) of the patients; they represented
45 countries. Foreign-born patients had a median residen-
cy of 4 years in the United Kingdom. There was no signif-
icant difference between patients infected with susceptible
or drug-resistant M. tuberculosis with respect to patient
country or continent of birth. However, highly significant
associations existed between continent of birth and lineage
(Table 4). Lineages I, II, and III were significantly associ-
ated with southeastern Asia, Europe, and the Indian sub-
continent, respectively. Lineage IV, in contrast, was
globally distributed but had a negative association with
Europe. This finding provides strong evidence for geo-
graphic structuring in M. tuberculosis populations.
Discussion
Synonymous nucleotide polymorphisms reflect neutral
genomic variation, which remains informative, even in
genes that have recently experienced positive selection
attributable to introducing antimicrobial agents. By
sequencing widely at multiple gene loci around the chro-
mosome in a population sample of M. tuberculosis iso-
lates, selection bias is avoided and all neutral variation
within the sequenced regions will be identified. The
indexed variation is highly unlikely to arise by conver-
gence, which provides a robust base for constructing a
phylogenetic tree. Our data support the belief that M.
tuberculosis is a strictly clonal organism, with no evidence
of lateral gene transfer. 
Individual sSNPs are confined to clonally related organ-
isms and accumulated by subsequent generations. Each of
the lineages defined here can be defined on the basis of
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Table 3. Characteristic features of the four major lineages of Mycobacterium tuberculosis with respect to M. bovis 
Silent single nucleotide polymorphism 
Nonsynonymous 
base substitutions
Species/lineage 
TbD1 region 
of difference 
rpoB 
3243 
T 
rpoB 
2646 
G 
katG 
87 
A 
katG 
609 
T 
oxyR 
285 
A 
oxyR 
37 
T 
katG 
1388 
G 
ahpC 
–46 
A 
Spoligotype 
signature spacer 
deletion 
M. tuberculosis 
Lineage I 
–  – – – – – – – –  1–34 
M. tuberculosis 
Lineage II 
–  + – – – – – + –  33–36 
M. tuberculosis 
Lineage III 
–  – + – – – – – + 4–8,  23–24 
M. tuberculosis 
Lineage IV 
+  – – – – – + – –  29–32  and  34 
M. bovis   +  – – + + + – – –  39–43 
Table 4. Relationship between Mycobacterium tuberculosis lineage and continent of birth of patient
a 
Europe  Africa  Indian subcontinent  Southeast Asia 
Lineage n Eur 
Not 
Eur OR  p  value  Afr
Not 
Afr OR  p  value ISC
Not 
ISC OR  p  value SEA 
Not 
SEA OR p  value 
I  17  5  12 0.86  0.997  1  16 0.17 0.079  1  16  0.12  0.034  10  7  28.8  0.00001
II 118  59  59  6.4   0.00001  33 85  1.34 0.473 19  99  0.2  0.00001  4 114  0.21 0.006 
III 50  3  47  0.1  0.00001  9  41  0.58 0.245  37  13  11.31  0.00001  0 50  0.0  0.009 
IV  40  5  35 0.25  0.005  15  25 2.04 0.08  15  25  1.36  0.514  5  35  1.66 0.166 
Total 225  72  153     58  167     72  153      19 206     
aOR, odds ratio; Eur, Europe; Afr, Africa; ISC, Indian subcontinent; SEA, southeast Asia. single sSNPs, yet the resultant maximum parsimony tree
provides a robust and unifying phylogeny for M. tuberculo-
sis. The documented population diversity is relatively
recent, demonstrated by SSTs that represent almost all of
the phylogenetic nodes. In contrast, M. tuberculosis and M.
bovis separated from a common ancestor more distantly,
which reinforces the evidence that M. tuberculosis could
not have arisen from M. bovis, as previously thought.
Although we have sequenced a small number of M.
tuberculosis complex isolates, our data support the evolu-
tionary scenario described by Brosch et al. (13). M. microti
is a subdivision of the M. bovis lineage, diverging after the
separation of M. bovis from its common ancestor with M.
tuberculosis. M. africanum type I, which cannot be distin-
guished from M. tuberculosis on the basis of neutral varia-
tion in the genes sequenced in this study, can be
distinguished from M. tuberculosis SST-1 by the presence
of the TbD1 region. Taken together, the sequence data sup-
port divergence of M. africanum type I from a common
ancestor with M. tuberculosis before the subsequent diver-
gence of M. microti and  M. bovis. Analyzing silent
nucleotide polymorphisms in gyrB, which has been used to
distinguish members of the M. tuberculosis complex
(38,39), would provide further neutral sequence variation
to support the evolutionary scenario. 
M. tuberculosis isolates in England and Wales represent
four clearly defined lineages. Although the isolates were
all obtained from patients residing in the United Kingdom,
the patients represented 45 countries of birth, from four
continents. The population is not globally representative;
for example, few patients originated from the Americas.
Nevertheless, the strong geographic structuring of the M.
tuberculosis population is striking. M. tuberculosis is an
obligate human pathogen, with a delay between initial
infection and the development of clinical disease (often up
to 5 years) and long periods of latency between disease
control and subsequent clinical reactivation. The evolution
and global dissemination of M. tuberculosis are by defini-
tion associated with the activities of its human host.
Although foreign-born patients may have been infected
with  M. tuberculosis in the United Kingdom, the short
median residency in the United Kingdom and the lack of
strain clustering support the hypothesis that these are
imported strains reflecting M. tuberculosis populations in
the patient’s country of birth. Clonal expansion of geo-
graphically restricted, genetically distinct lineages presum-
ably reflects the previously geographically limited human
population movements, with higher rates of transmission
within, rather than between, geographic regions. No single
M. tuberculosis lineage dominates in African-born
patients. As in human populations, Africa appears to be a
melting pot for genetic diversity. This fact may reflect the
dissemination of M. tuberculosis by ancient human migra-
tion and trade routes but could be further elucidated by
analysis of unselected isolates obtained in Africa. 
Unlike lineages I, II and III, lineage IV is globally dis-
tributed, with no discernible geographic association. Not
only is it the only lineage possessing the TbD1 region of
difference, in common with M. bovis, M. microti, and M.
africanum type I (13), but a large proportion of the isolates
possess only a single IS6110 copy, and isolates from the
lineage are negatively associated with antimicrobial drug
resistance. These data suggest that M. tuberculosis isolates
from lineage IV are more closely related to the common
ancestor of the M. tuberculosis complex, unexposed to
antimicrobial selection pressure, and provide evidence to
support the hypothesis that M. tuberculosis isolates pos-
sessing a single IS6110 copy may be ancestral (40,41). In
contrast, isolates possessing a high number of IS6110
copies are present in all four M. tuberculosis lineages,
which reflects independent IS6110 transposition events in
different parts of the phylogeny.
Geographic structuring of a clonal population will
result in genetically and phenotypically distinct M. tuber-
culosis populations, which may explain, in part, the geo-
graphically variable response to vaccination with M. bovis
BCG, or striking differences in clinical features, such as
the predominance of extrapulmonary disease in patients
originally from the Indian subcontinent. This finding may
also have implications for the successful development of
new TB vaccines. Nucleotide substitutions arising under
neutral, positive, and negative pressure will all become
fixed, inherited by all clonal descendants. Analyzing muta-
tions that confer antimicrobial drug resistance provides an
insight into this evolutionary process. By definition, resist-
ance-conferring mutations are associated with phenotypic
resistance absolutely. The genes involved all encode essen-
tial metabolic functions, restricting nonsynonymous
nucleotide substitutions. The data demonstrate that the
most frequently reported resistance-conferring mutations
are present in all lineages, which implies that they have
arisen independently on multiple separate occasions; how-
ever, phenotypically antimicrobial drug resistance is sig-
nificantly associated with lineage. The significantly
greater proportion of phenotypically resistant isolates with
the katG 315 mutation in lineage III and the observation that
the mutation is not present in all isolates within clonally
related subbranches of the tree confirms the relatively
recent influence of antimicrobial drug selection pressure.
This finding implies that isolates within the lineage may be
biochemically more susceptible to acquiring the same
resistance conferring mutation. Rifampicin resistance and
multidrug-resistant TB isolates were unrelated to lineage,
although the numbers were relatively small (52 phenotyp-
ically rifampicin-resistant isolates, of which 46 were mul-
tidrug resistant).
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strains, CDC1551 and H37Rv, are closely related and
come from the same major lineage (lineage II, SST-2).
This relation has implications for sSNP analyses based on
comparison of only these genomes, collapsing subbranch-
es and skewing any resultant phylogenetic tree (14,29).
Although this tendency can be reduced slightly by com-
paring genomes that are genetically more divergent, the
lack of horizontal gene transfer in a clonal population
means that variation in other branches of the phylogeny
will not be revealed. In fact, only four of the sSNPs
described here can be resolved by genome comparison of
the four completed genome sequences M. tuberculosis
H37Rv (17), CDC1551 (15), strain 210 (www.tigr.org),
and M. bovis (18). None were used in the SNP analysis
performed by Gutacker et al. (14). By sequencing widely
at multiple gene loci around the chromosome, we have
identified all the indexable genetically neutral variation
(sSNPs) within the sequenced regions. Although
Sreevatsan et al. used a similar approach in their study of
26 structural genes, which included regions of all seven
genes sequenced in this study (19), the isolates were
selected from a large collection of M. tuberculosis strains
in part on diversity in IS6110 RFLP (introducing a bias
towards high copy number strains), and the number of iso-
lates sequenced at each locus varied, with no defined min-
imum dataset. We identified a similar level of genomic
sequence diversity, but by using an unbiased population
approach, we have shown phylogenetically significant
neutral variation. 
The phylogeny described here is unambiguous and can
be defined with a limited number of sSNPs. These could
easily be identified with rapid screening techniques.
Simultaneous identification of nsSNPs associated with
antimicrobial drug resistance would provide data valuable
for clinical, epidemiologic, and evolutionary purposes in a
single, cost-effective, and highly portable format that is
amenable to electronic database comparisons (16).
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